DiscGenics Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Private

  • Employees
  • 40

Employees

  • Latest Deal Type
  • Series D
  • (Cancelled)

  • Investors
  • 7

DiscGenics General Information

Description

Developer of a regenerative cell-based biologic drug therapies intended to alleviate pain and restore function in patients with degenerative diseases of the spine. The company's offers an allogeneic, injectable, and homologous cell therapy that utilizes biomedically engineered progenitor cells derived from intervertebral disc tissue to treat diseases of the disc, enabling patients to have access to a non-surgical and regenerative alternative for chronic back pain.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 5940 West Harold Gatty Drive
  • Salt Lake City, UT 84116
  • United States
+1 (801)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Vertical(s)
Corporate Office
  • 5940 West Harold Gatty Drive
  • Salt Lake City, UT 84116
  • United States
+1 (801)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

DiscGenics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series D) Cancelled Clinical Trials - General
4. Later Stage VC (Series C) 04-Dec-2020 Completed Clinical Trials - General
3. Debt - PPP 14-Apr-2020 Completed Clinical Trials - General
2. Later Stage VC (Series B) 22-Sep-2017 $14.5M $21.2M Completed Clinical Trials - General
1. Later Stage VC (Series A) 30-Nov-2013 $7.2M $7.2M Completed Pre-Clinical Trials
To view DiscGenics’s complete valuation and funding history, request access »

DiscGenics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C-1
Series C
Nonvoting Series C
Nonvoting Series B 53,387 $0.001000 $0.24 $4.03 $4.03 1x $4.03 0.31%
Series B 3,921,454 $0.001000 $0.24 $4.03 $4.03 1x $4.03 22.72%
To view DiscGenics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

DiscGenics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a regenerative cell-based biologic drug therapies intended to alleviate pain and restore function in patien
Drug Discovery
Salt Lake City, UT
40 As of 2025

Melville, NY
 

Melbourne, Australia
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

DiscGenics Competitors (2)

One of DiscGenics’s 2 competitors is BioRestorative Therapies, a Corporation company based in Melville, NY.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
BioRestorative Therapies Corporation Melville, NY
Mesoblast Corporation Melbourne, Australia
You’re viewing 2 of 2 competitors. Get the full list »

DiscGenics Patents

DiscGenics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023406314-A1 Capped syringes and methods of sealing same Pending 01-Dec-2022
EP-4626520-A1 Capped syringes and methods of sealing same Pending 01-Dec-2022
EP-4626520-A4 Capped syringes and methods of sealing same Pending 01-Dec-2022
US-20240181169-A1 Capped syringes and methods of sealing same Pending 01-Dec-2022
WO-2024119046-A1 Capped syringes and methods of sealing same Inactive 01-Dec-2022 A61J1/05
To view DiscGenics’s complete patent history, request access »

DiscGenics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

DiscGenics Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
CareNet PE-Backed Company Minority
Ci:z Investment Corporate Venture Capital Minority
Eagle Fund SP1 Venture Capital Minority
Medical Incubator Japan Venture Capital Minority
Saisei Ventures Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

DiscGenics FAQs

  • When was DiscGenics founded?

    DiscGenics was founded in 2008.

  • Where is DiscGenics headquartered?

    DiscGenics is headquartered in Salt Lake City, UT.

  • What is the size of DiscGenics?

    DiscGenics has 40 total employees.

  • What industry is DiscGenics in?

    DiscGenics’s primary industry is Drug Discovery.

  • Is DiscGenics a private or public company?

    DiscGenics is a Private company.

  • What is DiscGenics’s current revenue?

    The current revenue for DiscGenics is .

  • How much funding has DiscGenics raised over time?

    DiscGenics has raised $73M.

  • Who are DiscGenics’s investors?

    CareNet, Ci:z Investment, Eagle Fund SP1, Medical Incubator Japan, and Saisei Ventures are 5 of 7 investors who have invested in DiscGenics.

  • Who are DiscGenics’s competitors?

    BioRestorative Therapies and Mesoblast are competitors of DiscGenics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process